Home Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer
Article
Licensed
Unlicensed Requires Authentication

Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer

  • Henry R. Maun , Daniel Kirchhofer and Robert A. Lazarus
Published/Copyright: June 11, 2010
Biological Chemistry
From the journal Volume 391 Issue 8

Abstract

Proteases represent a large class of enzymes with crucial biological functions. Although targeting various relevant proteases for therapeutic intervention has been widely investigated, structurally related proteins lacking proteolytic activity (pseudo-proteases) have received relatively little attention. Two distinct clinically relevant cancer pathways that contain signaling proteins with pseudo-protease domains include the Met and Hedgehog (Hh) pathways. The receptor tyrosine kinase Met pathway is driven by hepatocyte growth factor (HGF), a plasminogen-related ligand that binds Met and activates intracellular pathways resulting in cell proliferation, angiogenesis, motility and survival. HGF is a disulfide-linked α/β-heterodimer having a trypsin serine protease-like β-chain. The Hh pathway is driven by Sonic hedgehog (Shh), which has a Zn2+ metalloprotease fold and binds Patched1 (Ptc1), which de-represses Smoothened and ultimately activates Gli-dependent transcription. Although HGF and Shh differ in structure and function, the pseudo-catalytic sites of both HGF and Shh are crucial for signal transduction. For HGF, this region binds the Met β-propeller domain, which leads to Met dimerization and signaling. For Hh, this region binds to the antagonist receptor Hedgehog-interacting protein (Hhip) and most probably to Ptc1 as well. Thus, for both HGF and Hh pathways, targeting ligand pseudo-active sites represents a new strategy for regulation.


Corresponding author

Received: 2010-3-9
Accepted: 2010-4-22
Published Online: 2010-06-11
Published in Print: 2010-08-01

©2010 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Guest Editorial
  2. Highlight: The Biology of Proteolytic Systems
  3. Highlight: 6th General Meeting of the International Proteolysis Society
  4. Structure, mechanism and inhibition of γ-secretase and presenilin-like proteases
  5. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions
  6. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce β-amyloid related to Alzheimer's disease
  7. Proteases in lymphocyte killer function: redundancy, polymorphism and questions remaining
  8. Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer
  9. Proteolysis of platelet receptors in humans and other species
  10. Blunting the knife: development of vaccines targeting digestive proteases of blood-feeding helminth parasites
  11. Impaired turnover of autophagolysosomes in cathepsin L deficiency
  12. Nuclear cysteine cathepsin variants in thyroid carcinoma cells
  13. Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer
  14. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis
  15. Hydrophilic residues surrounding the S1 and S2 pockets contribute to dimerisation and catalysis in human dipeptidyl peptidase 8 (DP8)
  16. Molecular contortionism – on the physical limits of serpin ‘loop-sheet’ polymers
  17. The substrate specificity profile of human granzyme A
  18. Use of granzyme B-based fluorescent protein reporters to monitor granzyme distribution and granule integrity in live cells
Downloaded on 6.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/bc.2010.098/html
Scroll to top button